stockrow
Friday 6 November 2026
Export SIBN’s income statement to Excel — free account
SiBone
SIBN Healthcare Medical Devices
SiBone’s revenue for fiscal 2025 (year ended December 2025) was $200.9 million, up 20.2% from fiscal 2024.
- Revenue
- +14.5%
- EPS
- +26.7%
- Free cash flow
- +31.1%
- Total debt
- +0.33%
Quarter to September 2026, against a year earlier
24.48
0.21
+0.87%
Follow SIBN
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 42 | 48 | 55 | 67 | 73 | 90 | 106 | 139 | 167 | 201 | 221 | +19.0% | 232 | 268 | 310 | +15.6% | |
| Gross margin, % | 87.73 | 89.35 | 91.27 | 89.91 | 87.87 | 88.43 | 85.24 | 78.78 | 79.03 | 79.57 | 79.40 | (8.2) pt | ||||||
| EBT | (21) | (23) | (17) | (38) | (44) | (57) | (61) | (43) | (31) | (19) | (14) | (0.9%) | ||||||
| EBT margin, % | (48.90) | (48.01) | (31.51) | (57.06) | (59.54) | (62.75) | (57.57) | (31.20) | (18.49) | (9.41) | (6.20) | +39.5 pt | ||||||
| Net income | (21) | (23) | (17) | (38) | (44) | (57) | (61) | (43) | (31) | (19) | (14) | (0.9%) | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 12.70 | 13.84 | 6.97 | 2.72 | 2.53 | 2.72 | 3.11 | 3.61 | 4.03 | 4.68 | 4.91 | (10.5%) | |||||
| Earnings | (6.21) | (6.65) | (2.20) | (1.55) | (1.50) | (1.71) | (1.79) | (1.13) | (0.75) | (0.44) | (0.31) | (25.5%) | ||||||
| Cash flow | (5.06) | (5.06) | (1.83) | (1.28) | (1.06) | (1.19) | (1.22) | (0.49) | (0.30) | (0.02) | 0.14 | (47.4%) | ||||||
| Capex | (0.13) | (0.14) | (0.12) | (0.10) | (0.09) | (0.19) | (0.28) | (0.20) | (0.25) | (0.20) | (0.23) | +4.4% | ||||||
| Free cash flow | (5.19) | (5.19) | (1.94) | (1.38) | (1.14) | (1.39) | (1.50) | (0.69) | (0.55) | (0.21) | (0.09) | (29.9%) | ||||||
| Book value | (32.81) | (37.32) | 11.34 | 2.55 | 5.83 | 4.06 | 2.87 | 4.41 | 4.03 | 4.13 | 4.11 | n/m | ||||||
| Shares, m | 3 | 3 | 8 | 25 | 29 | 33 | 34 | 38 | 41 | 43 | 44 | +32.9% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | 1.45 | 1.45 | 3.00 | 7.89 | 11.84 | 8.17 | 4.28 | 5.77 | 3.48 | 4.22 | 4.92 | 5.2 | ||||||
| P/B | 0.00 | 0.00 | 1.84 | 8.43 | 5.13 | 5.48 | 4.63 | 4.73 | 3.48 | 4.77 | 5.88 | 3.8 | ||||||
| EV/Sales | 2.09 | 2.09 | 1.64 | 7.11 | 9.82 | 6.94 | 3.71 | 4.84 | 2.80 | 3.66 | 4.43 | 4.5 | ||||||
| EV/FCF | (8.20) | (8.20) | (5.89) | (14.05) | (21.69) | (13.62) | (7.72) | (25.36) | (20.43) | (81.02) | (233.06) | (20.6) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (17) | (18) | (15) | (32) | (31) | (40) | (42) | (19) | (12) | (1) | 6 | (30.0%) | |||||
| Capex | 0 | 0 | (1) | (2) | (3) | (6) | (10) | (8) | (10) | (8) | (10) | +38.8% | ||||||
| Free cash flow | (17) | (18) | (15) | (34) | (33) | (46) | (51) | (27) | (23) | (9) | (4) | (6.8%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 23 | 26 | 127 | 93 | 205 | 159 | 116 | 188 | 181 | 191 | 195 | +26.5% | |||||
| Net debt | 1 | 16 | (83) | (53) | (157) | (112) | (62) | (130) | (115) | (112) | (111) | n/m | ||||||
| Shareholders’ equity | (109) | (129) | 90 | 63 | 169 | 134 | 98 | 169 | 167 | 178 | 185 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (54.71) | (61.22) | (20.02) | (30.06) | (25.69) | (27.35) | (35.20) | (22.34) | (13.42) | (8.06) | (5.57) | +46.7 pt | |||||
| ROIC | 0.00 | 0.00 | (107.88) | (215.31) | (194.61) | (144.08) | (102.96) | (74.41) | (42.06) | (21.38) | (14.10) | (21.4) pt | ||||||
| ROE | 17.29 | 19.35 | 89.08 | (50.13) | (37.61) | (37.25) | (52.64) | (32.38) | (18.38) | (10.97) | (7.67) | (28.3) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | 168 | 183 | 262 | 295 | 352 | 357 | 344 | 349 | 376 | — | +10.6% | |||||
| Revenue/emp, $m | 0.00 | 0.29 | 0.30 | 0.26 | 0.25 | 0.26 | 0.30 | 0.40 | 0.48 | 0.53 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026
SiBone vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| LMRI Lumexa Imaging Holdings, Inc. | $1.3B | — (loss-making) | 38.0× | +7.82% (above 0%: growing) | n/m | +257.54% (above 0%: growing) | 14.72% | 8.72% | Compare |
| ATEC Alphatec Holdings, Inc. | $1.2B | — (loss-making) | — (loss-making) | +12.55% (above 0%: growing) | n/m | −149.22% (below 0%: shrinking) | 71.55% | 1.47% | Compare |
| PRCT PROCEPT BioRobotics Corporation | $1.2B | — (loss-making) | — (loss-making) | +17.96% (above 0%: growing) | n/m | −1.57% (below 0%: shrinking) | 66.28% | (27.85%) | Compare |
| IART Integra LifeSciences Holdings Corporation | $1.1B | 83.0× | 26.0× | +2.27% (above 0%: growing) | n/m | +232.94% (above 0%: growing) | 51.04% | 4.60% | Compare |
| SIBN SiBone | $1.1B | — (loss-making) | — (loss-making) | +14.49% (above 0%: growing) | n/m | +31.13% (above 0%: growing) | 79.29% | (7.81%) | |
| IRMD iRadimed Corporation | $1.1B | 44.9× | 39.6× | +14.15% (above 0%: growing) | +15.91% (above 0%: growing) | +18.58% (above 0%: growing) | 76.26% | 33.63% | Compare |
| CBLL CeriBell, Inc. | $1.0B | — (loss-making) | — (loss-making) | +29.89% (above 0%: growing) | n/m | −19.65% (below 0%: shrinking) | 89.77% | (70.03%) | Compare |
| AHCO AdaptHealth Corp. | $1.0B | — (loss-making) | — (loss-making) | +10.90% (above 0%: growing) | n/m | −23.58% (below 0%: shrinking) | 15.40% | (20.91%) | Compare |
| QDEL QuidelOrtho Corporation | $880.5M | — (loss-making) | — (loss-making) | −11.57% (below 0%: shrinking) | n/m | +120.70% (above 0%: growing) | 46.79% | (1.21%) | Compare |
| Median of peers | $1.1B | — | 38.0× | +11.73% | — | +8.51% | 58.66% | 0.13% |
Pay and ownership Proxy statement filed 21 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 7.45m | 10.00m | 65.95 |
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Read the proxy statement